2019

16 September, 2019 R

Lipidor’s New Share Issue Achieves 540 % Subscription

On Friday, 13 September 2019, the subscription period ended for Lipidor AB's ("the Company") issuance of units before the Company’s planned listing on the Nasdaq… Read more

09 September, 2019 R

Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against mild to moderate… Read more

27 August, 2019 R

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market [updated]

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum of 2,100,000 units… Read more

26 August, 2019

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum of 2,100,000 units… Read more

20 June, 2019

Decisions from Annual General Meeting of Lipidor AB, 20 June 2019

(Stockholm 20 June, 2019) On 20 June2019, the Annual General Meeting (”AGM”) of Lipidor AB (publ) was held in Stockholm. Read below for a summary of… Read more

14 January, 2019

Lipidor AB successfully completes private placement of 20 MSEK

14 January 2019, Stockholm, Sweden. Lipidor AB, a Swedish drug development company with an ongoing fully financed Phase III study for a psoriasis medication, has… Read more

Load more
16 September, 2019 R

Lipidor’s New Share Issue Achieves 540 % Subscription

On Friday, 13 September 2019, the subscription period ended for Lipidor AB's ("the Company") issuance of units before the Company’s planned listing on the Nasdaq… Read more

09 September, 2019 R

Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against mild to moderate… Read more

27 August, 2019 R

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market [updated]

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum of 2,100,000 units… Read more

Load more